JP2012504660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504660A5 JP2012504660A5 JP2011530297A JP2011530297A JP2012504660A5 JP 2012504660 A5 JP2012504660 A5 JP 2012504660A5 JP 2011530297 A JP2011530297 A JP 2011530297A JP 2011530297 A JP2011530297 A JP 2011530297A JP 2012504660 A5 JP2012504660 A5 JP 2012504660A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- isolated
- antibody
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 148
- 239000000427 antigen Substances 0.000 claims description 125
- 102000036639 antigens Human genes 0.000 claims description 125
- 108091007433 antigens Proteins 0.000 claims description 125
- 238000000034 method Methods 0.000 claims description 125
- 239000012634 fragment Substances 0.000 claims description 58
- 230000002163 immunogen Effects 0.000 claims description 46
- 108700035708 EsaB Proteins 0.000 claims description 28
- 150000001720 carbohydrates Chemical class 0.000 claims description 28
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 22
- 239000002671 adjuvant Substances 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 15
- 150000004676 glycans Chemical class 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 14
- 229920001282 polysaccharide Polymers 0.000 claims description 14
- 239000005017 polysaccharide Substances 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 241000295644 Staphylococcaceae Species 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 7
- 101710197219 Alpha-toxin Proteins 0.000 claims description 7
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 7
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 7
- 241000606768 Haemophilus influenzae Species 0.000 claims description 7
- 108010006464 Hemolysin Proteins Proteins 0.000 claims description 7
- 101710124951 Phospholipase C Proteins 0.000 claims description 7
- 101710188053 Protein D Proteins 0.000 claims description 7
- 101710132893 Resolvase Proteins 0.000 claims description 7
- 239000002776 alpha toxin Substances 0.000 claims description 7
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 7
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 7
- 239000003228 hemolysin Substances 0.000 claims description 7
- 229960000814 tetanus toxoid Drugs 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 238000011109 contamination Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 38
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 241000191940 Staphylococcus Species 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 206010041917 Staphylococcal abscess Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 101000728671 Comamonas testosteroni Bifunctional aspartate aminotransferase and L-aspartate beta-decarboxylase Proteins 0.000 description 1
- -1 EsaC Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 208000022338 anthrax infection Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10319608P | 2008-10-06 | 2008-10-06 | |
| US10319008P | 2008-10-06 | 2008-10-06 | |
| US61/103,190 | 2008-10-06 | ||
| US61/103,196 | 2008-10-06 | ||
| US17077909P | 2009-04-20 | 2009-04-20 | |
| US61/170,779 | 2009-04-20 | ||
| PCT/US2009/059648 WO2010042481A1 (en) | 2008-10-06 | 2009-10-06 | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504660A JP2012504660A (ja) | 2012-02-23 |
| JP2012504660A5 true JP2012504660A5 (OSRAM) | 2012-06-07 |
Family
ID=41382468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530297A Pending JP2012504660A (ja) | 2008-10-06 | 2009-10-06 | 細菌ｅａｐ、ｅｍｐおよび／またはａｄｓａタンパク質に関連する組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110262477A1 (OSRAM) |
| EP (1) | EP2341929B1 (OSRAM) |
| JP (1) | JP2012504660A (OSRAM) |
| CN (1) | CN102333540B (OSRAM) |
| AU (1) | AU2009302582A1 (OSRAM) |
| BR (1) | BRPI0920041A2 (OSRAM) |
| CA (1) | CA2739581A1 (OSRAM) |
| WO (1) | WO2010042481A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180221466A9 (en) * | 2006-06-12 | 2018-08-09 | Glaxosmithkline Biologicals S.A. | Use of alpha-toxin for treating and preventing staphylococcus infections |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| CN101951948B (zh) * | 2007-08-31 | 2015-12-09 | 芝加哥大学 | 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物 |
| BR112012010223A2 (pt) * | 2009-10-30 | 2016-12-06 | Novartis Ag | purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares |
| CN101914144B (zh) * | 2010-04-30 | 2013-01-09 | 浙江大学 | 金黄色葡萄球菌荚膜多糖和蛋白质偶联物及制备方法和用途 |
| BR112013000097B1 (pt) | 2010-07-02 | 2022-02-01 | The University Of Chicago | Polipeptídeo imunogênico isolado, composição imunogênica e seu uso |
| EP2614074A1 (en) * | 2010-09-09 | 2013-07-17 | The University of Chicago | Methods and compositions involving protective staphylococcal antigens |
| CN103906535B (zh) | 2011-08-15 | 2017-07-14 | 芝加哥大学 | 与葡萄球菌蛋白a的抗体相关的组合物和方法 |
| WO2013162746A1 (en) * | 2012-04-26 | 2013-10-31 | University Of Chicago | Staphylococcal coagulase antigens and methods of their use |
| CN104703622B (zh) | 2012-04-26 | 2017-05-24 | 芝加哥大学 | 与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法 |
| CN102993308B (zh) * | 2012-09-29 | 2014-11-05 | 重庆原伦生物科技有限公司 | 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原hi2及制备方法和应用 |
| DK2917360T3 (da) | 2012-11-06 | 2020-03-30 | Medimmune Llc | Antistoffer mod S. aureus-overflade-determinanter |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| BR112015029838A2 (pt) | 2013-05-31 | 2017-09-26 | Genentech Inc | anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus |
| KR20160015286A (ko) | 2013-05-31 | 2016-02-12 | 제넨테크, 인크. | 항-세포벽 테이코산 항체 및 접합체 |
| ES2962694T3 (es) | 2014-05-02 | 2024-03-20 | Momenta Pharmaceuticals Inc | Composiciones y procedimientos relacionados con construcciones de Fc manipuladas |
| BR112017011478A2 (pt) | 2014-12-03 | 2018-02-27 | Genentech, Inc. | composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante |
| CN107206102A (zh) | 2014-12-03 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途 |
| WO2016095832A1 (en) * | 2014-12-18 | 2016-06-23 | The University Of Hong Kong | Immunotherapeutic targets against staphylococcus aureus |
| CN105424930A (zh) * | 2015-11-23 | 2016-03-23 | 天津科技大学 | 一种快速检测金黄色葡萄球菌的方法 |
| ES2972740T3 (es) * | 2016-03-02 | 2024-06-14 | Momenta Pharmaceuticals Inc | Procedimientos relacionados con construcciones de Fc modificadas genéticamente |
| IL263213B2 (en) | 2016-05-23 | 2024-05-01 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| EP3535292A1 (en) * | 2016-11-03 | 2019-09-11 | Oxford University Innovation Limited | Fusion polypeptides derived from staphylococcus aureus antigens |
| EP3565588A4 (en) | 2017-01-06 | 2020-12-16 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATING TO MODIFIED FC CONSTRUCTIONS |
| JP7220502B2 (ja) * | 2017-03-15 | 2023-02-10 | ロンドン スクール オブ ハイジーン アンド トロピカル メディシン | 全細胞ワクチン |
| CA3088851A1 (en) * | 2018-01-05 | 2019-07-11 | Azitra Inc | Auxotrophic strains of staphylococcus bacterium |
| US20230390373A1 (en) * | 2020-05-22 | 2023-12-07 | Versitech Limited | A live strain of staphylococcus aureus and uses thereof |
| CN116472342A (zh) * | 2020-05-22 | 2023-07-21 | 港大科桥有限公司 | 一种金黄色葡萄球菌的活菌株及其用途 |
| CN118598380B (zh) * | 2024-08-08 | 2024-10-22 | 生态环境部南京环境科学研究所 | 一种长效修复石油化工企业地下水石油烃污染的方法 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3949064A (en) | 1973-10-26 | 1976-04-06 | Baxter Laboratories, Inc. | Method of detecting antigens or antibodies |
| US4174384A (en) | 1975-06-30 | 1979-11-13 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| JPS5452794A (en) | 1977-09-30 | 1979-04-25 | Kousaku Yoshida | Extracting of polysacchride from capusle containing epidermis staphylococus |
| US4367110A (en) | 1979-07-02 | 1983-01-04 | Toppan Printing Co. | Decorative laminate and a manufacturing method therefor |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
| US4338298A (en) | 1980-04-04 | 1982-07-06 | Endowment And Research Foundation At Montana State University | Vaccine for passive immunization against enteric colibacillosis and method of use |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
| US4748018A (en) | 1984-02-07 | 1988-05-31 | Stolle Research & Development Corp. | Method of passive immunization of mammals using avian antibody |
| JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5310687A (en) | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US5221605A (en) | 1984-10-31 | 1993-06-22 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
| AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
| US5858652A (en) | 1988-08-30 | 1999-01-12 | Abbott Laboratories | Detection and amplification of target nucleic acid sequences |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| SE8901687D0 (sv) | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | Fibronectin binding protein as well as its preparation |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| US5620896A (en) | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
| WO1993018784A1 (en) | 1992-03-26 | 1993-09-30 | Microcarb, Inc. | Monospecific polyclonal antibodies to shiga-like toxins |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| WO1994002620A2 (en) | 1992-07-27 | 1994-02-03 | Pioneer Hi-Bred International, Inc. | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5846709A (en) | 1993-06-15 | 1998-12-08 | Imclone Systems Incorporated | Chemical process for amplifying and detecting nucleic acid sequences |
| FR2708288B1 (fr) | 1993-07-26 | 1995-09-01 | Bio Merieux | Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé. |
| ES2210262T3 (es) | 1993-09-22 | 2004-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas. |
| US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5648240A (en) | 1994-05-24 | 1997-07-15 | Texas A&M University | MHC II analog from Staphylococcus aureus |
| NZ287118A (en) | 1994-05-28 | 1999-01-28 | Tepnel Medical Ltd | Method of detecting and amplifying oligonucleotides |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| US5942391A (en) | 1994-06-22 | 1999-08-24 | Mount Sinai School Of Medicine | Nucleic acid amplification method: ramification-extension amplification method (RAM) |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5935825A (en) | 1994-11-18 | 1999-08-10 | Shimadzu Corporation | Process and reagent for amplifying nucleic acid sequences |
| US6770278B1 (en) | 1994-12-02 | 2004-08-03 | Central Biomedia, Inc. | Methods of making and using immunoglobulin (Ig) compositions |
| US5548066A (en) | 1994-12-02 | 1996-08-20 | Central Biomedia, Inc. | Failure of passive transfer immune serum and method of making same |
| US5843650A (en) | 1995-05-01 | 1998-12-01 | Segev; David | Nucleic acid detection and amplification by chemical linkage of oligonucleotides |
| WO1997014800A1 (en) | 1995-10-16 | 1997-04-24 | Smithkline Beecham Plc | Novel saliva binding protein |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5612473A (en) | 1996-01-16 | 1997-03-18 | Gull Laboratories | Methods, kits and solutions for preparing sample material for nucleic acid amplification |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| DK0950068T3 (da) | 1996-05-16 | 2006-02-13 | Texas A & M Univ Sys | Kollagen-bindende proteinsammensatninger og fremgangsmade til anvendelse |
| US5939291A (en) | 1996-06-14 | 1999-08-17 | Sarnoff Corporation | Microfluidic method for nucleic acid amplification |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US6294177B1 (en) | 1996-09-11 | 2001-09-25 | Nabi | Staphylococcus aureus antigen-containing whole cell vaccine |
| US5849546A (en) | 1996-09-13 | 1998-12-15 | Epicentre Technologies Corporation | Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| KR100564268B1 (ko) | 1996-10-23 | 2006-03-27 | 와이어쓰 | 백신 |
| US5849497A (en) | 1997-04-03 | 1998-12-15 | The Research Foundation Of State University Of New York | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker |
| US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
| US5916776A (en) | 1997-08-27 | 1999-06-29 | Sarnoff Corporation | Amplification method for a polynucleotide |
| US6756361B1 (en) | 1997-10-14 | 2004-06-29 | Nabi | Enterococcus antigens and vaccines |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| US5932451A (en) | 1997-11-19 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Method for unbiased mRNA amplification |
| WO2000002523A2 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases Department Of The Army | Vaccine against staphylococcus intoxication |
| JP4714342B2 (ja) | 1998-08-31 | 2011-06-29 | ザ プラヴアスト フエロウス アンド スカラース オブ ザ カレツヂ オブ ザ ハリー アンド アンデイヴアイデツド トリニテイ オブ クイーン エリザベス ニヤー ダブリン | コアグラーゼ陰性スタフィロコカス菌に由来のポリペプチド及びポリヌクレオチド |
| AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| AU1813701A (en) | 1999-12-03 | 2001-06-12 | Celltech Chiroscience Limited | Interleukin-1 muteins useful as vaccine adjuvants |
| US6482240B1 (en) | 1999-12-07 | 2002-11-19 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Method of making a collagen membrane from porcine skin |
| US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
| SE0000514D0 (sv) | 2000-02-17 | 2000-02-17 | Biostapro Ab | A 52 kDa protein from coagulase negative staphylococci and fragments |
| EP1333858B8 (en) | 2000-11-07 | 2006-06-14 | Immunovaccine Technologies Inc. | Vaccines with enhanced immune response and methods for their preparation |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| US20020169288A1 (en) | 2001-03-15 | 2002-11-14 | Magnus Hook | Collagen-binding adhesin from staphylococcus epidermidis and method of use |
| GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| US7115264B2 (en) | 2001-11-05 | 2006-10-03 | Inhibitex | Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections |
| DE60230670D1 (de) | 2001-12-11 | 2009-02-12 | Merck & Co Inc | Staphylococcus aureus exopolysaccharid und verfahren |
| WO2004043407A2 (en) | 2002-11-12 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
| AU2003295520B8 (en) | 2002-11-12 | 2011-05-19 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for Staphylococcal infections |
| US20080095792A1 (en) * | 2004-09-17 | 2008-04-24 | Anderson Annaliesa S | Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus |
| US8758765B2 (en) * | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2009
- 2009-10-06 WO PCT/US2009/059648 patent/WO2010042481A1/en not_active Ceased
- 2009-10-06 EP EP09793315.4A patent/EP2341929B1/en not_active Not-in-force
- 2009-10-06 US US13/122,793 patent/US20110262477A1/en not_active Abandoned
- 2009-10-06 JP JP2011530297A patent/JP2012504660A/ja active Pending
- 2009-10-06 CA CA2739581A patent/CA2739581A1/en not_active Abandoned
- 2009-10-06 BR BRPI0920041A patent/BRPI0920041A2/pt not_active IP Right Cessation
- 2009-10-06 CN CN200980146554.XA patent/CN102333540B/zh not_active Expired - Fee Related
- 2009-10-06 AU AU2009302582A patent/AU2009302582A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504660A5 (OSRAM) | ||
| CA2739581A1 (en) | Compositions and methods related to bacterial eap, emp, and/or adsa proteins | |
| JP2012522808A5 (OSRAM) | ||
| JP2013534532A5 (OSRAM) | ||
| KR101773368B1 (ko) | 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법 | |
| CN101951948B (zh) | 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物 | |
| JP2021535921A (ja) | 多価肺炎球菌ワクチン | |
| US20090053235A1 (en) | Use of alpha-toxin for treating and preventing staphylococcus infections | |
| CN102481352A (zh) | 金黄色葡萄球菌抗原的免疫原性组合物 | |
| CN103068838B (zh) | 基于重组蛋白的抗链球菌感染疫苗 | |
| CN113164580B (zh) | 肺炎球菌融合蛋白疫苗 | |
| TW201332568A (zh) | 對抗表現碳青黴烯酶（ｃａｒｂａｐｅｎｅｍａｓｅ）之細菌之免疫組合物及方法 | |
| KR20240099160A (ko) | 다가 폐렴구균 백신 | |
| US20160074497A1 (en) | Staphylococcus live cell vaccines | |
| US9789176B2 (en) | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus | |
| JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
| JP5096326B2 (ja) | ブドウ球菌感染を治療および予防するためのＰａｎｔｏｎ−Ｖａｌｅｎｔｉｎｅロイコシジンの使用 | |
| EP3383884A1 (en) | Method for preventing or treating nosocomial pneumonia | |
| US8404245B2 (en) | Immunization of non-human mammals against Streptococcus equi | |
| KR20220107166A (ko) | 스타필로코커스 펩티드 및 사용 방법 | |
| Wang et al. | Staphylococcus aureus | |
| RU2815390C2 (ru) | Поливалентные пневмококковые вакцины | |
| US20110171224A1 (en) | PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION | |
| Lee | Staphylococcus aureus vaccine | |
| JP2008545383A (ja) | 細菌感染の予防または治療のためのペニシリン結合タンパク質またはそのポリヌクレオチドもしくは抗体の使用方法 |